Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
Tabla de Políticas Médicas
| ID | Título | Revisión | Descripción | Acceso |
|---|---|---|---|---|
| P1.002.010 | Ruconest (C1 Esterase Inhibitor [recombinant]) | Sep 2026 | Ruconest is a recombinant c1 esterase inhibitor indicated for the treatment of acute attacks of hereditary... | Ver |
| P1.002.011 | Ultomiris® (ravulizumab-cwvz) | Jun 2026 | Ravulizumab-cwvz (ultomiris™) is a humanized monoclonal antibody with a high affinity for c5, a protein... | Ver |
| P1.002.012 | Eculizumab Products [eculizumab (Soliris®), eculizumab-aagh(Epysqli), eculizumab-aeeb (Bkemv)] Injection | Sep 2026 | Eculizumab is a terminal complement (c5) inhibitor. this medical drug criteria applies to the reference... | Ver |
| P1.002.013 | Adstiladrin® (nadofaragene firadenovec-vncg) | Feb 2026 | Adstiladrin is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult... | Ver |
| P1.002.014 | AMTAGVI (Lifileucel) | Sep 2026 | Melanoma accounts for less than 2% of all skin cancers as well as all cancer deaths in the united states.... | Ver |
| P1.002.015 | AUCATZYL (Obecabtagene autoleucel) | Sep 2026 | Aucatzyl is a cd19-directed genetically modified autologous t cell immunotherapy indicated for the treatment... | Ver |
| P1.002.016 | ENCELTO (Revakinagene taroretcel-lwey) | Sep 2026 | Macular telangiectasia is a progressive ocular disease with two forms, type 1 (mactel1) and type 2 (mactel2).... | Ver |
| P1.002.017 | KEBILIDI (Eladocagene exuparvovec-tneq) | Sep 2026 | ... | Ver |
| P1.002.018 | LANTIDRA (Donislecel) | Sep 2026 | Lantidra (donislecel-jujn) is an allogeneic pancreatic islet cell therapy approved by the fda in june 2023.... | Ver |
| P1.002.019 | LAVIV (Azficel-T) | Sep 2026 | Azficel-t is an autologous cellular product composed of fibroblasts indicated for improvement of the... | Ver |
| P1.002.021 | OMISIRGE (Omidubicel-onlv) | Sep 2026 | Omisirge (omidubicel-onlv) is an ex-vivo expanded cell therapy derived from umbilical cord blood, engineered... | Ver |
| P1.002.022 | RETHYMIC (Allogeneic processed thymus tissue – agdc) | Sep 2026 | ... | Ver |
| P1.002.023 | RYONCIL (Remestemcel-L-rknd) | Sep 2026 | Remestemcel-l-rknd (ryoncil) is fda-approved for the treatment of steroid-refractory acute graft-versushost... | Ver |
| P1.002.026 | TECELRA (Afamitresgene autoleucel) | Sep 2026 | Tecelra (afamitresgene autoleucel) is a melanoma-associated antigen a4 (magea4)-directed genetically modified... | Ver |
| P1.002.027 | ZEVASKYN (Prademagene zamikeracel) | Sep 2026 | [dystrophic epidermolysis bullosa (deb) is caused by mutations in the collagen type vii alpha 1 chain... | Ver |
| P1.002.028 | AXTLE (pemetrxed) | Sep 2026 | Pemetrexed (alimta) was initially approved by the u.s. food and drug administration (fda) in february 2004... | Ver |
| P1.002.033 | Gefitinib | Sep 2026 | Iressa (gefitinib) is a tyrosine kinase inhibitor indicated for metastatic non-small cell lung cancer (nsclc)... | Ver |
| PP.001.001 | Dose Rounding of Drug Covered Under The Medical Benefit | May 2026 | ... | Ver |
| PP.001.002 | Leuprolide | May 2026 | (leuprolide acetate) – a drug that is a manufactured version of a hormone. it is a hormone-releasing... | Ver |
| PP.001.004 | Coverage Guideline for Orphan Drugs and Off-Label and Labeled Use of FDA Approved Drugs | Jan 2026 | Triple s salud has a procedure designed to ensure the evaluation of requests for coverage of covered... | Ver |